Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
Website:
http://actuatetherapeutics.comNext earnings report:
29 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Mon, 18 Nov 2024 14:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
Included in screeners
ACTU Latest News
CHICAGO and FORT WORTH, Texas, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), announced that it will participate in “ Webinar Wednesday ” hosted by Lantern Pharma on October 30, 2024.
CHICAGO and FORT WORTH, Texas, Sept. 09, 2024 (GLOBE NEWSWIRE) -- – Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), provided an update on its Phase 1/2 trial of elraglusib in relapsed/refractory Ewing Sarcoma (r/r EWS).
This week was another slow week for pricings, with two companies making their public debut, along with three SPACs. On the filing side, offshore-focused drilling equipment and aftermarket service provider, HMH Holding, filed to raise $100 million. Three IPOs are currently scheduled to list in the week ahead, all based in the Asia Pacific region. One SPAC is also expected to price.
What type of business is Actuate Therapeutics?
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.
What sector is Actuate Therapeutics in?
Actuate Therapeutics is in the Healthcare sector
What industry is Actuate Therapeutics in?
Actuate Therapeutics is in the Biotechnology industry
What country is Actuate Therapeutics from?
Actuate Therapeutics is headquartered in United States
What is Actuate Therapeutics website?
https://actuatetherapeutics.com
Is Actuate Therapeutics in the S&P 500?
No, Actuate Therapeutics is not included in the S&P 500 index
Is Actuate Therapeutics in the NASDAQ 100?
No, Actuate Therapeutics is not included in the NASDAQ 100 index
Is Actuate Therapeutics in the Dow Jones?
No, Actuate Therapeutics is not included in the Dow Jones index
When was Actuate Therapeutics the previous earnings report?
No data
When does Actuate Therapeutics earnings report?
The next expected earnings date for Actuate Therapeutics is 29 November 2024